Badanie dotyczące stosowania amiwantamabu w monoterapii lub w skojarzeniu z innymi środkami leczniczymi u pacjentów z nawrotowym/przerzutowym rakiem głowy i szyi (OrigAMI-4)
Otwarte badanie fazy 1b/2 dotyczące stosowania amiwantamabu w monoterapii i amiwantamabu w skojarzeniu ze standardowymi środkami terapeutycznymi u pacjentów z nawrotowym/przerzutowym rakiem płaskonabłonkowym głowy i szyi
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metastatic head and neck cancer. The study will also confirm the recommended Phase 2 combination dose (RP2CD) for amivantamab in addition to paclitaxel. The safety and preliminary efficacy of amivantamab in addition to pembrolizumab will also be determined in perioperative (before and after surgery) setting in participants with resectable locally advanced head and neck squamous cell carcinoma (HNSCC).
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Study Contact
- Numer telefonu: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Lokalizacje studiów
-
-
-
Beijing, Chiny, 100142
- Zakończony
- Beijing Cancer Hospital of Peking University
-
Cheng Du Shi, Chiny, 610041
- Rekrutacyjny
- West China School of Medicine/West China Hospital, Sichuan University
-
Linyi, Chiny, 276002
- Zakończony
- Linyi Cancer Hospital
-
Shanghai, Chiny, 200120
- Rekrutacyjny
- Shanghai East Hospital
-
Shanghai, Chiny, 200032
- Rekrutacyjny
- Fudan Cancer Hospital
-
Wuhan, Chiny, 430022
- Rekrutacyjny
- Union Hospital Tongji Medical College of Huazhong University of Science and Technology
-
-
-
-
-
Avignon, Francja, 84918
- Rekrutacyjny
- Institut Sainte Catherine
-
Lille, Francja, 59000
- Rekrutacyjny
- Centre Oscar Lambret
-
Nantes, Francja, 44000
- Rekrutacyjny
- CHU Nantes
-
Paris, Francja, 75248
- Rekrutacyjny
- Institut Curie
-
Villejuif, Francja, 94805
- Rekrutacyjny
- Gustave Roussy
-
-
-
-
-
Barcelona, Hiszpania, 08908
- Rekrutacyjny
- Inst. Cat. Doncologia-H Duran I Reynals
-
Barcelona, Hiszpania, 08035
- Rekrutacyjny
- Hosp Univ Vall D Hebron
-
Madrid, Hiszpania, 28034
- Rekrutacyjny
- Hosp. Univ. Ramon Y Cajal
-
Madrid, Hiszpania, 28041
- Rekrutacyjny
- Hosp. Univ. 12 de Octubre
-
-
-
-
-
Nagoya, Japonia, 464-8681
- Rekrutacyjny
- Aichi Cancer Center
-
Tokyo, Japonia, 160-0023
- Rekrutacyjny
- Tokyo Medical University Hospital
-
-
-
-
-
Seoul, Korea Południowa, 05505
- Rekrutacyjny
- Asan Medical Center
-
Seoul, Korea Południowa, 03080
- Rekrutacyjny
- Seoul National University Hospital
-
Seoul, Korea Południowa, 06351
- Rekrutacyjny
- Samsung Medical Center
-
Seoul, Korea Południowa, 03722
- Rekrutacyjny
- Severance Hospital Yonsei University Health System
-
-
-
-
-
Kuala Lumpur, Malezja, 59100
- Rekrutacyjny
- University Malaya Medical Centre
-
Kuala Lumpur, Malezja, 59100
- Rekrutacyjny
- Pantai Hospital Kuala Lumpur
-
-
-
-
-
Essen, Niemcy, 45147
- Rekrutacyjny
- Universitaetsklinikum Essen
-
Leipzig, Niemcy, 04103
- Zakończony
- Universitaetsklinikum Leipzig
-
Stuttgart, Niemcy, 70174
- Rekrutacyjny
- Klinikum der Landeshauptstadt Stuttgart
-
-
-
-
-
Gdansk, Polska, 80 214
- Rekrutacyjny
- Uniwersyteckie Centrum Kliniczne
-
Gliwice, Polska, 44-102
- Rekrutacyjny
- Centrum Onkologii Instytut im M Sklodowskiej Curie Oddzial w Gliwicach
-
Warsaw, Polska, 02 781
- Rekrutacyjny
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
-
-
-
California
-
La Jolla, California, Stany Zjednoczone, 92093
- Zakończony
- University of California at San Diego Moores Cancer Center
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Rekrutacyjny
- University of Colorado Denver Anschultz Medical Campus
-
-
Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06520
- Rekrutacyjny
- Yale Cancer Center
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- Rekrutacyjny
- The University of Chicago Medical Center (UCMC)
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21201
- Rekrutacyjny
- University of Maryland School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02115
- Rekrutacyjny
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- Rekrutacyjny
- University of Michigan Rogel Cancer Center
-
Detroit, Michigan, Stany Zjednoczone, 48201 2013
- Rekrutacyjny
- Karmanos Cancer Institute
-
-
Missouri
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Rekrutacyjny
- Washington University School Of Medicine
-
-
New Jersey
-
New Brunswick, New Jersey, Stany Zjednoczone, 08901
- Rekrutacyjny
- Rutgers Cancer Institute of New Jersey
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27599
- Rekrutacyjny
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Rekrutacyjny
- Cleveland Clinic
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Rekrutacyjny
- University of Utah Huntsman Cancer Institute
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22903
- Rekrutacyjny
- University of Virginia
-
Fairfax, Virginia, Stany Zjednoczone, 22031
- Rekrutacyjny
- Virginia Cancer Specialists
-
-
-
-
-
Changhua, Tajwan, 500
- Rekrutacyjny
- Changhua Christian Hospital
-
Kaohsiung City, Tajwan, 833
- Rekrutacyjny
- Kaohsiung Chang Gung Memorial Hospital
-
Taipei, Tajwan, 100
- Rekrutacyjny
- National Taiwan University Hospital
-
Taipei, Tajwan, 112
- Rekrutacyjny
- Taipei Veterans General Hospital
-
Taoyuan, Tajwan, 33382
- Rekrutacyjny
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Cambridge, Zjednoczone Królestwo, CB2 0QQ
- Rekrutacyjny
- Addenbrooke's Hospital
-
Guildford, Zjednoczone Królestwo, GU2 7XX
- Rekrutacyjny
- The Royal Surrey County Hospital NHS Foundation Trust
-
London, Zjednoczone Królestwo, SW3 6JJ
- Rekrutacyjny
- Royal Marsden Hospital
-
London, Zjednoczone Królestwo, W1T 7HA
- Rekrutacyjny
- University College London Hospitals
-
London, Zjednoczone Królestwo, SM2 5PT
- Rekrutacyjny
- Royal Marsden Hospital (Sutton)
-
London, Zjednoczone Królestwo, W12 0HS
- Zakończony
- Imperial College London and Imperial College Healthcare NHS Trust
-
Manchester, Zjednoczone Królestwo, M20 4BX
- Rekrutacyjny
- The Christie Nhs Foundation Trust
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Cohorts 1 to 5: Have histologically or cytologically confirmed recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that is considered incurable by local therapies or for Cohort 6: have histologically or cytologically confirmed locally advanced (L/A) HNSCC that is considered curable by surgery Acceptable prior lines of therapy will be determined according to specific cohort 1, 2, 3A and 3B: (a) The eligible primary tumor locations are the oropharynx, oral cavity, hypopharynx, or larynx; (b) Any known p16 status of tumor must be negative (Note: All participants with an oropharyngeal tumor must have results of p16 status, per local testing); (c) Participants must provide local testing results of programmed cell death ligand 1 (PD-L1) status, if available; Cohort 4: (d) Patients must have primary tumor location in oropharynx. Unknown primary tumors are not included (e) Primary tumor must be HPV-positive, confirmed by positive p16 test or high-risk human papillomavirus (HPV) in-situ hybridization (ISH) in tissue (current or archival) (f) Participants must provide local testing results of PD-L1 status, if available; Cohort 5 (g) The eligible primary tumor locations are the oropharynx, oral cavity, hypopharynx, or larynx; (h) HPV status must be known (either positive or negative) for patients with primary tumor location in oropharynx with p16 test or high-risk HPV ISH in tissue; (i) Participants must provide local testing results of PD-L1 status; Cohort 6: (j) The eligible primary tumor locations are the oropharynx, oral cavity, hypopharynx, or larynx; (k) Any known p16 status of tumor must be negative Note: All participants with an oropharyngeal tumor must have results of p16 status, per local testing Participants must provide local testing results of PD-L1 status (l) Participants must have Stage III or IVa disease (American Joint Committee on Cancer Staging Manual, 8th edition). Participants must have resectable disease
- Participants in Cohorts 1, 2, 3B, 4 and 5 must have measurable disease according to RECIST version 1.1. Participants in Cohort 3A and Cohort 6 must have evaluable disease (defined as having at least 1 non-target lesion according to RECIST version 1.1.
- Cohorts 1, 2, 3A, 3B, 4, and 5 only: Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less prior to the first dose of study treatment (except for alopecia or post-radiation skin changes [any grade], Grade less than or equal to [<=]2 peripheral neuropathy and Grade <=2 hypothyroidism stable on hormone replacement)
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Participant must have adequate organ and bone marrow function as follows, without history of red blood cell transfusion, platelet transfusion, or use of granulocyte colony-stimulating factor within 7 days prior to the date of the laboratory test.
Participants should have: a) Hemoglobin >=9 grams per deciliter (g/dL); b) Neutrophils >=1.5 x 10^3/mcg; c) Platelets >=100 x 10^3/mcg
Exclusion Criteria:
- Uncontrolled illness including any medical history or current (non-infectious) interstitial lung disease (ILD)/ pneumonitis/ pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening
- Participant with untreated brain metastases leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation
- Participant with a history of clinically significant cardiovascular disease
- Received prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks or 4 half-lives, whichever is longer, before the first administration of study treatment. The maximum required washout is 28 days
- Received radiotherapy for palliative purposes within 7 days of the first administration of study treatment
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Cohort 1: Amivantamab Monotherapy (Dose Expansion)
Participants will receive subcutaneous injection of amivantamab monotherapy 1600 milligrams (mg) (2240 mg, if body weight >=80 kilograms [kg]) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) once every week (q1w) for the remainder of Cycle 1 (Days 8 and 15), and every 3 weeks (q3w) from Cycle 2 onwards. |
Amivantamab will be administered subcutaneously.
Inne nazwy:
|
|
Eksperymentalny: Cohort 2: Amivantamab + Pembrolizumab (Dose Expansion Including Safety Run-in)
Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight >=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards, along with intravenous (IV) injection of pembrolizumab 200 mg q3w (on Day 1 of each 21-day cycle). |
Amivantamab will be administered subcutaneously.
Inne nazwy:
Pembrolizumab will be administered intravenously.
Inne nazwy:
|
|
Eksperymentalny: Cohort 3A (Dose Confirmation): Amivantamab + Paclitaxel
Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight >=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards, along with intravenous injection of paclitaxel 175 mg/m^2 q3w (on Day 1 of each 21-day cycle) in dose confirmation Cohort 3A. The recommended Phase 2 combination dose (RP2CD) of amivantamab will be determined in conjunction with study evaluation team (SET) in this dose confirmation Cohort 3A. |
Amivantamab will be administered subcutaneously.
Inne nazwy:
Paclitaxel will be administered intravenously.
Inne nazwy:
|
|
Eksperymentalny: Cohort 3B (Dose Expansion): Amivantamab + Paclitaxel
Participants will receive subcutaneous injection of amivantamab at the determined RP2CD in addition to intravenous injection of paclitaxel 175 mg/m^2 q3w (on Day 1 of each 21-day cycle) as confirmed by SET in Cohort 3A. |
Amivantamab will be administered subcutaneously.
Inne nazwy:
Paclitaxel will be administered intravenously.
Inne nazwy:
|
|
Eksperymentalny: Cohort 4: Amivantamab Monotherapy
Participants will receive subcutaneous injection of amivantamab monotherapy 1600 mg (2240 mg, if body weight >=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards. |
Amivantamab will be administered subcutaneously.
Inne nazwy:
|
|
Eksperymentalny: Cohort 5: Pembrolizumab + Amivantamab + Carboplatin (Dose Expansion)
Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight >=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards in addition to intravenous injection of pembrolizumab 200 mg on Day 1 of each cycle, and carboplatin (area under the concentration-time curve [AUC] 5 milligram per milliliter [mg/ml]*min) q3w on Day 1 of Cycles 1-6. |
Amivantamab will be administered subcutaneously.
Inne nazwy:
Pembrolizumab will be administered intravenously.
Inne nazwy:
Carboplatin will be administered intravenously.
Inne nazwy:
|
|
Eksperymentalny: Cohort 6: Amivantamab + Pembrolizumab
Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight >=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight >=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2, along with intravenous injection of pembrolizumab 200 mg q3w (on Day 1 of each 21-day cycle) (Neoadjuvant Phase). In the adjuvant phase, pembrolizumab IV (200 mg) will be administered q3w from Adjuvant Cycle 1 Day 1 to Adjuvant Cycle 15 Day 1 and amivantamab SC 2,400 mg (3,360 mg for >80 kg) will be administered q3w from Adjuvant Cycle 4 Day 1 to Adjuvant Cycle 15 Day 1. |
Amivantamab will be administered subcutaneously.
Inne nazwy:
Pembrolizumab will be administered intravenously.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Cohorts 1, 2, 3B, 4 and 5: Objective Response Rate
Ramy czasowe: 2 years and 2 months
|
ORR is defined as the proportion of participants who achieve either a partial response (PR) or complete response (CR), as defined by investigator assessment using Response Criteria in Solid Tumors (RECIST) version 1.1. |
2 years and 2 months
|
|
Cohort 3A: Number of Participants With Dose-limiting Toxicities (DLT)
Ramy czasowe: Up to 21 days
|
Number of participants with DLTs will be reported. A DLT is defined as any of the following: treatment delay of greater than (>) 28 days due to unresolved toxicity, non-hematologic toxicity of Grade 3 or higher, hematologic toxicity of Grade 4 neutropenia persisting for >7 days or Grade 3 or higher thrombocytopenia with clinically significant bleeding or neutropenic fever of any grade, and liver enzyme elevation. |
Up to 21 days
|
|
Cohort 3A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Severity
Ramy czasowe: 2 years and 1 month
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. |
2 years and 1 month
|
|
Cohort 6: Major Pathologic Response (MPR)
Ramy czasowe: 2 years and 2 months
|
The participants who achieve MPR at the time of surgery. |
2 years and 2 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Cohorts 1, 2, 3B, 4 and 5: Duration of Response (DoR)
Ramy czasowe: 2 years and 2 months
|
DoR is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR. |
2 years and 2 months
|
|
Cohorts 1, 2, 3B, 4 and 5: Clinical Benefit Rate (CBR)
Ramy czasowe: 2 years and 2 months
|
CBR is defined as the percentage of participants achieving a confirmed complete or partial response, or durable stable disease (the second disease assessment) as defined by RECIST version 1.1. |
2 years and 2 months
|
|
Cohorts 1, 2, 3B, 4 and 5: Progression-free Survival (PFS)
Ramy czasowe: 2 years and 2 months
|
PFS is defined as the time from the first administration of study treatment until the date of objective disease progression or death, whichever comes first, based on investigator assessment using RECIST version 1.1. |
2 years and 2 months
|
|
Cohorts 1, 2, 3B, 4, 5 and 6: Overall Survival (OS)
Ramy czasowe: 2 years and 2 months
|
OS is defined as the time from the first administration of study treatment until the date of death due to any cause. |
2 years and 2 months
|
|
Cohorts 1, 2, 3B, 4, 5 and 6: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Severity
Ramy czasowe: 2 years and 1 month
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse events. |
2 years and 1 month
|
|
Cohort 1 and 4: Maximum Observed Serum Concentration (Cmax) of Amivantamab
Ramy czasowe: Predose up to 168 hours post dose on Day 1
|
Cmax is defined as maximum observed serum concentration of amivantamab. |
Predose up to 168 hours post dose on Day 1
|
|
Cohort 1 and 4: Time to Maximum Observed Serum Concentration (Tmax) of Amivantamab
Ramy czasowe: Predose up to 168 hours post dose on Day 1
|
Tmax is defined as time to maximum observed serum concentration of amivantamab. |
Predose up to 168 hours post dose on Day 1
|
|
Cohort 1 and 4: Area Under the Serum Concentration Curve Verses Time Curve From Time t1 to t2 (AUC[t1-t2]) of Amivantamab
Ramy czasowe: Predose up to 168 hours post dose on Day 1
|
AUC(t1-t2) is defined as area under the serum concentration versus time curve from time t1 to time t2 of amivantamab. |
Predose up to 168 hours post dose on Day 1
|
|
Cohort 1 and 4: Area Under the Curve From Time Zero to tau (AUC[0-tau]) of Amivantamab
Ramy czasowe: Predose up to 168 hours post dose on Day 1
|
AUC(0-tau) is defined as area under the curve from time 0 to tau hours of amivantamab. |
Predose up to 168 hours post dose on Day 1
|
|
Cohort 1 and 4: Trough Serum Concentration (Ctrough) of Amivantamab
Ramy czasowe: Predose up to 168 hours post dose on Day 1
|
Ctrough is defined as the serum concentration of amivantamab. |
Predose up to 168 hours post dose on Day 1
|
|
Cohort 1 and 4: Accumulation Ratio (R) of Amivantamab
Ramy czasowe: Predose up to 168 hours post dose on Day 1
|
Accumulation ratio (R) is calculated as area under the serum concentration-time curve from time zero to 168 hours (AUC[0-168]) value at Cycle 2 Day 1 dose divided by AUC(0-168) value after Cycle 1 Day 1 amivantamab dose. |
Predose up to 168 hours post dose on Day 1
|
|
Cohort 6: Event-Free Survival (EFS)
Ramy czasowe: 2 years and 2 months
|
EFS is defined as the time from the first administration of study treatment until the date of radiographic disease progression, local or distant progression or recurrence as assessed with imaging or biopsy as indicated, or death due to any cause. |
2 years and 2 months
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory
- Nowotwory według typu histologicznego
- Nowotwory głowy i szyi
- Nowotwory gruczołowe i nabłonkowe
- Rak
- Rak, płaskonabłonkowy
- Rak płaskonabłonkowy głowy i szyi
- Organiczne chemikalia
- Węglowodory
- Cykloparafiny
- Węglowodory, Alicyklic
- Węglowodory, cykliczne
- Terpeny
- Kompleksy koordynacyjne
- Taksoidy
- Cyklodekan
- Diterpenes
- Karboplatyna
- Paklitaksel
- pembrolizumab
- Amivantamab
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 61186372HNC2002
- 61186372HNC2002 (Inny identyfikator: Janssen Research & Development, LLC)
- 2023-508418-40-00 (Identyfikator rejestru: EUCT number)
- 2023 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .